131 related articles for article (PubMed ID: 27771167)
1. Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy.
Lee JY; Kim K; Lee YS; Kim HY; Nam EJ; Kim S; Kim SW; Kim JW; Kim YT
Gynecol Oncol; 2016 Dec; 143(3):622-627. PubMed ID: 27771167
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
Duska LR; Java JJ; Cohn DE; Burger RA
Gynecol Oncol; 2015 Nov; 139(2):221-7. PubMed ID: 26335594
[TBL] [Abstract][Full Text] [Related]
3. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
Cohn DE; Kim KH; Resnick KE; O'Malley DM; Straughn JM
J Clin Oncol; 2011 Apr; 29(10):1247-51. PubMed ID: 21383297
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.
Mehta DA; Hay JW
Gynecol Oncol; 2014 Mar; 132(3):677-83. PubMed ID: 24463160
[TBL] [Abstract][Full Text] [Related]
5. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
Wysham WZ; Schaffer EM; Coles T; Roque DR; Wheeler SB; Kim KH
Gynecol Oncol; 2017 May; 145(2):340-345. PubMed ID: 28291545
[TBL] [Abstract][Full Text] [Related]
6. The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.
Hinde S; Epstein D; Cook A; Embleton A; Perren T; Sculpher M
Value Health; 2016 Jun; 19(4):431-9. PubMed ID: 27325335
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer.
Ortega A; Dranitsaris G; Sturgeon J; Sutherland H; Oza A
Gynecol Oncol; 1997 Sep; 66(3):454-63. PubMed ID: 9299261
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.
Barnett JC; Alvarez Secord A; Cohn DE; Leath CA; Myers ER; Havrilesky LJ
Cancer; 2013 Oct; 119(20):3653-61. PubMed ID: 23921967
[TBL] [Abstract][Full Text] [Related]
9. Patient preferences in advanced or recurrent ovarian cancer.
Havrilesky LJ; Alvarez Secord A; Ehrisman JA; Berchuck A; Valea FA; Lee PS; Gaillard SL; Samsa GP; Cella D; Weinfurt KP; Abernethy AP; Reed SD
Cancer; 2014 Dec; 120(23):3651-9. PubMed ID: 25091693
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.
Petrillo M; Paris I; Vizzielli G; Amadio G; Cosentino F; Salutari V; Scambia G; Fagotti A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S952-8. PubMed ID: 26036187
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy with bevacizumab (i.p.) can prolong survival time of patients with advanced ovarian cancer after cytoreduction.
DU F; Li P; Chen J; Gong Z; Chi C; Hu B; Chu H
Neoplasma; 2017; 64(1):108-113. PubMed ID: 27881011
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
Oh J; Barve M; Matthews CM; Koon EC; Heffernan TP; Fine B; Grosen E; Bergman MK; Fleming EL; DeMars LR; West L; Spitz DL; Goodman H; Hancock KC; Wallraven G; Kumar P; Bognar E; Manning L; Pappen BO; Adams N; Senzer N; Nemunaitis J
Gynecol Oncol; 2016 Dec; 143(3):504-510. PubMed ID: 27678295
[TBL] [Abstract][Full Text] [Related]
13. Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women.
Chishti U; Aziz AB
J Pak Med Assoc; 2015 Mar; 65(3):306-9. PubMed ID: 25933567
[TBL] [Abstract][Full Text] [Related]
14. Patient preference for a long-acting recombinant FSH product in ovarian hyperstimulation in IVF: a discrete choice experiment.
van den Wijngaard L; Rodijk IC; van der Veen F; Gooskens-van Erven MH; Koks CA; Verhoeve HR; Mol BW; van Wely M; Mochtar MH
Hum Reprod; 2015 Feb; 30(2):331-7. PubMed ID: 25432926
[TBL] [Abstract][Full Text] [Related]
15. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
16. Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer.
Havrilesky LJ; Yang JC; Lee PS; Secord AA; Ehrisman JA; Davidson B; Berchuck A; Darcy KM; Maxwell GL; Reed SD
Cancer; 2019 Dec; 125(24):4399-4406. PubMed ID: 31454432
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab for Ovarian Cancer at High Risk of Progression: Reproducibility of Trial Results in 'Real-world' Patients.
Bertelli G; Drews F; Lutchman-Singh K
Anticancer Res; 2016 Sep; 36(9):4947-50. PubMed ID: 27630353
[TBL] [Abstract][Full Text] [Related]
18. Patients' preferences for gonadotrophin-releasing hormone analogs in in vitro fertilization.
van den Wijngaard L; van Wely M; Dancet EA; van Mello NM; Koks CA; van der Veen F; Mol BW; Mochtar MH
Gynecol Obstet Invest; 2014; 78(1):16-21. PubMed ID: 24942802
[TBL] [Abstract][Full Text] [Related]
19. Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer.
Behbakht K; Cohn DE; Straughn JM
Gynecol Oncol; 2018 Oct; 151(1):4-5. PubMed ID: 30068488
[No Abstract] [Full Text] [Related]
20. Addition of bevacizumab to neoadjuvant chemotherapy for Stage IV ovarian serous adenocarcinoma with multiple lymph node metastases: a case report.
Liu H; Shi Y; Zhang GN; Song SQ; Hu T
Eur J Gynaecol Oncol; 2015; 36(3):341-5. PubMed ID: 26189267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
